SiDMAP – Metabolomics for Drug Development
Skip to content
Home
About SiDMAP
Contact Us
Agi Hirshberg
Laszlo G. Boros, M.D.
Wai-Nang Paul Lee, M.D.
David Manheim
Technology
Targeted Tracer Fate Associations
Precursor/Product Isotope Matching
Applications
Products
Services
Publications
Metabolic Phenotyping
Targeted Tracer Fate Association Study (TTFAS)
SiDMAP Array
Proteomics
Pharmacology
Lipidomics
Mitochondrial Metabolism
Cancer Metabolism
Animal Studies
Clinical Studies
News
Order Services
Category Archives:
Publications
Metabolic Phenotyping
by
admin
Posted on
September 12, 2013
(more…)
Targeted Tracer Fate Association Study (TTFAS)
by
admin
Posted on
September 12, 2013
(more…)
SiDMAP Array
by
admin
Posted on
September 12, 2013
(more…)
Proteomics
by
admin
Posted on
September 12, 2013
(more…)
Pharmacology
by
admin
Posted on
September 12, 2013
(more…)
Lipidomics
by
admin
Posted on
September 12, 2013
(more…)
Mitochondrial Metabolism
by
admin
Posted on
September 12, 2013
(more…)
Cancer Metabolism
by
admin
Posted on
September 12, 2013
(more…)
Animal Studies
by
admin
Posted on
September 12, 2013
(more…)
Clinical Studies
by
admin
Posted on
September 12, 2013
(more…)
Search for:
News
SiDMAP’s scientific advisor delivers talk showing single [1,2-13C2]-D-Glucose tracer cross-labels intracellular stearic acid and better traces mechanistic rosiglitazone response than what was obtained with extracellular [U-13C18]-stearate incubation in a separate study using HepG2 cells.
Targeted tracer fate association study finds links among metformin, cholesterol, K-ras and pancreatic cancer growth-control
Combined genomics and targeted tracer fate association approach utilized in characterizing stress response in cancer
SiDMAP Collaboration with University of Utah School of Medicine Published in FASEB Journal
SiDMAP Collaboration With National Cancer Institute To Be Presented at The 2013 World Biotechnology Conference
Global Metabolomics Market to Reach $863.8 Million by 2017, According to a New Report by Global Industry Analysts, Inc.
SiDMAP studies of two Amgen anti-diabetic agents demonstrate mechanisms of glucose homeostatis regulation and energy metabolism.
